Table 2 Basic characteristics of included studies in this meta-analysis
Study | Year | Country | Sample size | Cancer type | Study period | Age (year) Median (range) | FIGO stage | Treatment | Study center | Follow-up (month) Median (range) | Endpoint | Cut-off value | HR analysis | Adjustment covariates for multivariate analysis | NOS score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Li, Y [10] | 2020 | China | 206 | Ovarian cancer | 2013–2016 | 58 | I-IV | Surgery | Single center | 1–80 | OS, PFS | 3 | Multivariate | Age, menopause, FIGO stage, histological subtype, histological grade, ascites, CA125, treatment, residual disease, chemosensitivity | 7 |
Li, Q [12] | 2021 | China | 1,038 | Endometrial cancer | 2012–2017 | 56 (51–61) | I-IV | Surgery | Single center | 1–84 | OS, PFS | 1 | Multivariate | TC, NLR, CA125, NPS, age, menopause, histological subtype, histological grade, FIGO stage, myometrial invasion, treatment | 8 |
Zhang, G [13] | 2021 | China | 698 | Cervical cancer | 2004–2015 | 51 | I-II | Surgery + CCRT | Multicenter | 56.2 (4.9–186.9) | OS, PFS | 3 | Multivariate | Age, BMI, FIGO stage, hemoglobin, histological type, lymph nodes metastasis, parametrial invasion, positive resection margin, SCC-Ag, PNI, HDR brachytherapy | 7 |
Bekos, C [14] | 2022 | Austria | 337 | Ovarian cancer | 2000–2015 | 59.54 | I-IV | Surgery + chemotherapy | Single center | 1–120 | OS, PFS | 2 | Multivariate | FIGO stage, age, histological grade, residual disease, histological type | 7 |
Jiang, L [15] | 2022 | China | 122 | Cervical cancer | 2016–2018 | 48.3 (32–67) | I-II | Surgery | Single center | 1–60 | OS | 3 | Multivariate | Age, histological type, histological grade, positive resection margin, SCC-Ag, tumor size, lymph nodes metastasis, FIGO stage, parametrial invasion, treatment | 7 |
Karakaş, S [16] | 2022 | Turkey | 168 | Ovarian cancer | 2015–2020 | 55.7 | I-IV | Surgery | Single center | 26.3 | OS | 1.5 | Multivariate | Menopause, FIGO stage, ascites, PNI | 8 |